Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 11
Submit an article Journal homepage
17,319
Views
152
CrossRef citations to date
0
Altmetric
Respiratory Medicine

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

Marlies WijsenbeekDepartment of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-4527-6962
ORCID Icon,
Michael KreuterCenter for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany;
,
Amy OlsonNational Jewish Health, Denver, CO, USA;
,
Aryeh FischerUniversity of Colorado School of Medicine, Denver, CO, USA; ORCID Iconhttp://orcid.org/0000-0003-2024-6780
ORCID Icon,
Elisabeth BendstrupDepartment of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark; ORCID Iconhttp://orcid.org/0000-0002-4238-6963
ORCID Icon,
Christopher D. WellsDecision Resources Group,Burlington, MA, USA;
,
Christopher P. DentonCentre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, UK;
,
Baher MounirBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany;
,
Leila Zouad-LejourBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany;
,
Manuel QuaresmaBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany;
&
Vincent CottinReference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, FranceORCID Iconhttp://orcid.org/0000-0002-5591-0955
ORCID Icon show all
Pages 2015-2024 | Received 11 Jun 2019, Accepted 19 Jul 2019, Published online: 02 Aug 2019

Citations (152)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Elisabeth Bendstrup, Sissel Kronborg-White, Janne Møller & Thomas Skovhus Prior. (2022) Current best clinical practices for monitoring of interstitial lung disease. Expert Review of Respiratory Medicine 16:11-12, pages 1153-1166.
Read now
Rémi Diesler & Vincent Cottin. (2022) Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Review of Respiratory Medicine 16:5, pages 541-553.
Read now
Ayako Takizawa, Mitsutoyo Kamita, Yasuhiro Kondoh, Masashi Bando, Masataka Kuwana & Yoshikazu Inoue. (2021) Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Current Medical Research and Opinion 37:2, pages 327-339.
Read now
Paroma Sarkar, Cristina Avram & Nazia Chaudhuri. (2020) The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Review of Respiratory Medicine 14:10, pages 1001-1008.
Read now
Oliver Distler, Elizabeth R. Volkmann, Anna Maria Hoffmann-Vold & Toby M. Maher. (2019) Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology 15:10, pages 1009-1017.
Read now

Articles from other publishers (147)

Maeve G. Macmurdo, Xinge Ji, Pratik Pimple, Amy L. Olson, Alex Milinovich, Blaine Martyn-Dow, Aman Pande, Alex Zajichek, Janine Bauman, Shaun Bender, Craig Conoscenti, David Sugano, Michael W. Kattan & Daniel A. Culver. (2024) Proportion and predictors of FVC decline in patients with interstitial lung disease. Respiratory Medicine 227, pages 107656.
Crossref
Yusuke Nakamura, Seiji Niho & Yasuo Shimizu. (2024) Cell-Based Therapy for Fibrosing Interstitial Lung Diseases, Current Status, and Potential Applications of iPSC-Derived Cells. Cells 13:11, pages 893.
Crossref
Ji Hoon Jang, Eun Jun Choe, So Young Jung, Junghae Ko, Dae-Wook KimJae Ha Lee. (2024) A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study. Medicine 103:20, pages e38226.
Crossref
Krystal L. Cleven, Rachel Zeig-Owens, Alexandra K. Mueller, Brandon Vaeth, Charles B. Hall, Jaeun Choi, David G. Goldfarb, David E. Schecter, Michael D. Weiden, Anna Nolan, Steve H. Salzman, Nadia Jaber, Hillel W. Cohen & David J. Prezant. (2024) Interstitial Lung Disease and Progressive Pulmonary Fibrosis: a World Trade Center Cohort 20-Year Longitudinal Study. Lung.
Crossref
Ziyi Zhang, Xiaoqian Ma, Junye Bai, Shu Xia, Qian Han & Qun Luo. (2024) Characterizing the lavage and serum cytokine profiles of interstitial pneumonia with autoimmune features and their implications for progressive fibrosis. Rheumatology 63:5, pages 1230-1239.
Crossref
Noriyuki Enomoto. (2024) Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review. Respiratory Investigation 62:3, pages 465-480.
Crossref
Chenyi Shao, Nana Xia, Yan Zhen, Xueliang Zhang, Ninghui Yan & Qiang Guo. (2024) Prognostic significance of natural killer cell depletion in predicting progressive fibrosing interstitial lung disease in idiopathic inflammatory myopathies. Frontiers in Immunology 15.
Crossref
Jeffrey P. Kanne, Christopher M. Walker, Anupama G. Brixey, Kevin K. Brown, Lydia Chelala, Ella A. Kazerooni, Simon L. F. Walsh & David A. Lynch. (2024) Progressive Pulmonary Fibrosis and Interstitial Lung Abnormalities: AJR Expert Panel Narrative Review . American Journal of Roentgenology.
Crossref
Malik A. Althobiani, Anne-Marie Russell, Joseph Jacob, Yatharth Ranjan, Amos A. Folarin, John R. Hurst & Joanna C. Porter. (2024) Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Frontiers in Medicine 11.
Crossref
Santiago Auteri & Anastasia Secco. (2024) Interstitial lung disease in primary Sjögren's syndrome. Revista Colombiana de Reumatología 31, pages S123-S131.
Crossref
Raquel García Sevila, Juan José Arenas Jiménez, Paloma Vela Casasempere, Ester Nofuentes Pérez & Ignacio Gayá García-Manso. (2024) Nintedanib in chronic fibrosing interstitial lung diseases. A case series. Heliyon 10:7, pages e28403.
Crossref
Katarzyna Bartold, Zofia Iskierko, Piyush Sindhu Sharma, Hung-Yin Lin & Wlodzimierz Kutner. (2024) Idiopathic pulmonary fibrosis (IPF): Diagnostic routes using novel biomarkers. Biomedical Journal, pages 100729.
Crossref
Canlin Li, Yuan Li, Xi Huang, Si Li, Kangzhuo Sangji & Rui Gu. (2024) Traditional Tibetan medicine: therapeutic potential in lung diseases. Frontiers in Pharmacology 15.
Crossref
Katharina Buschulte, Hans-Joachim Kabitz, Lars Hagmeyer, Peter Hammerl, Albert Esselmann, Conrad Wiederhold, Dirk Skowasch, Christoph Stolpe, Marcus Joest, Stefan Veitshans, Marc Höffgen, Phillen Maqhuzu, Larissa Schwarzkopf, Andreas Hellmann, Michael Pfeifer, Jürgen Behr, Rainer Karpavicius, Andreas Günther, Markus Polke, Philipp Höger, Vivien Somogyi, Christoph Lederer, Philipp Markart & Michael Kreuter. (2024) Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry. Respiratory Research 25:1.
Crossref
Min Hui, Xinwang Duan, Jiaxin Zhou, Mengtao Li, Qian Wang, Jiuliang Zhao, Yong Hou, Dong Xu & Xiaofeng Zeng. (2024) Prediction of progressive fibrosing interstitial lung disease in patients with systemic sclerosis: insight from the CRDC cohort study. RMD Open 10:1, pages e003715.
Crossref
Ruxandra Puiu, Nicoleta Stefania Motoc, Sergiu Lucaciu, Maria Victoria Ruta, Ruxandra-Mioara Rajnoveanu, Doina Adina Todea & Milena Adina Man. (2024) The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease—A Systematic Review. Biomolecules 14:3, pages 247.
Crossref
Sarah Barth, Colin Edwards, Rebecca Borton, Dan Beever, Wendy Adams, Gisli Jenkins, Elena Pizzo, Iain Stewart & Melissa Wickremasinghe. (2024) REMOTE-ILD study: Description of the protocol for a multicentre, 12-month randomised controlled trial to assess the clinical and cost-effectiveness of remote monitoring of spirometry and pulse oximetry in patients with interstitial lung disease. BMJ Open Respiratory Research 11:1, pages e002067.
Crossref
Emanuel Kolanko, Anna Cargnoni, Andrea Papait, Antonietta Rosa Silini, Piotr Czekaj & Ornella Parolini. (2024) The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery . European Respiratory Review 33:171, pages 230127.
Crossref
Gaetano Rea, Marialuisa Bocchino, Roberta Lieto, Roberta Eufrasia Ledda, Michele D’Alto, Marco Sperandeo, Raffaella Lucci, Patrizio Pasquinelli, Stefano Sanduzzi Zamparelli, Giorgio Bocchini, Tullio Valente & Giacomo Sica. (2024) The Unveiled Triad: Clinical, Radiological and Pathological Insights into Hypersensitivity Pneumonitis. Journal of Clinical Medicine 13:3, pages 797.
Crossref
Seok Young Koh, Jong Hyuk Lee, Hyungin Park & Jin Mo Goo. (2023) Value of CT quantification in progressive fibrosing interstitial lung disease: a deep learning approach. European Radiology.
Crossref
Thomas Koudstaal, Manuela Funke-Chambour, Michael Kreuter, Philip L. Molyneaux & Marlies S. Wijsenbeek. (2023) Pulmonary fibrosis: from pathogenesis to clinical decision-making. Trends in Molecular Medicine 29:12, pages 1076-1087.
Crossref
Anders Løkke, Luca Castello, Pedro Pinheiro Martins, Stéphane Soulard & Ole Hilberg. (2023) Burden of Disease and Productivity Loss in the European Economic Area in Patients Affected by Fibrosing Interstitial Lung Disease. Advances in Therapy 40:12, pages 5502-5518.
Crossref
Tobias Veit & Jürgen Behr. (2023) Interstitielle Lungenerkrankungen und andere progressive pulmonale FibrosenIdiopathic pulmonary fibrosis and other progressive pulmonary fibroses. Zeitschrift für Pneumologie 20:6, pages 333-342.
Crossref
María Martín-López & Patricia E. Carreira. (2023) The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis–Associated Interstitial Lung Disease. Journal of Clinical Medicine 12:20, pages 6680.
Crossref
David Singer, Benjamin Chastek, Andrew Sargent, Jonathan C. Johnson, Sharash Shetty, Craig Conoscenti & Elana J. Bernstein. (2023) Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization. BMC Pulmonary Medicine 23:1.
Crossref
Julien Guiot & Simon L.F. Walsh. (2023) The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis. European Respiratory Journal 62:3, pages 2300577.
Crossref
Yusuke Nakamura, Yasuo Shimizu, Mio Fujimaki-Shiraishi, Nobuhiko Uchida, Akihiro Takemasa & Seiji Niho. (2023) A Protective Effect of Pirfenidone in Lung Fibroblast–Endothelial Cell Network via Inhibition of Rho-Kinase Activity. Biomedicines 11:8, pages 2259.
Crossref
N. S. Lev & Yu. L. Mizernitskiy. (2023) Modern concepts of clinical variants and features of hypersensitivity pneumonitis in children. Meditsinskiy sovet = Medical Council:12, pages 182-191.
Crossref
Yu-Hsuan Chen, Tai-Ju Lee, Hsin-Jung Hsieh, Song-Chou Hsieh, Hao-Chien Wang, Yeun-Chung Chang, Chong-Jen Yu & Jung-Yien Chien. (2023) Clinical outcomes and risk factors of progressive pulmonary fibrosis in primary Sjögren’s syndrome-associated interstitial lung disease. BMC Pulmonary Medicine 23:1.
Crossref
Hongyan Fu, Ziyao Zheng, Zhenping Zhang, Yanjuan Yang, Jieda Cui, Zhaojun Wang, Jing Xue, Shuhong Chi, Mengshu Cao & Juan Chen. (2023) Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clinical Rheumatology 42:7, pages 1917-1929.
Crossref
Katarzyna B. Lewandowska, Monika Szturmowicz, Urszula Lechowicz, Monika Franczuk, Katarzyna Błasińska, Maria Falis, Kamila Błaszczyk, Małgorzata Sobiecka, Dorota Wyrostkiewicz, Izabela Siemion-Szcześniak, Małgorzata Bartosiewicz, Piotr Radwan-Röhrenschef, Adriana Roży, Joanna Chorostowska-Wynimko & Witold Z. Tomkowski. (2023) The Presence of T Allele (rs35705950) of the MUC5B Gene Predicts Lower Baseline Forced Vital Capacity and Its Subsequent Decline in Patients with Hypersensitivity Pneumonitis. International Journal of Molecular Sciences 24:13, pages 10748.
Crossref
Theodoros Karampitsakos, Marlies Wijsenbeek, Jose D. Herazo-Maya, Argyris Tzouvelekis & Michael Kreuter. 2023. Rare Diseases of the Respiratory System. Rare Diseases of the Respiratory System 23 39 .
Matthieu Pelletier-Galarneau, Emily Vandenbroucke, Minyi Lu & Olivia Li. (2023) Characteristics and key differences between patient populations receiving imaging modalities for coronary artery disease diagnosis in the US. BMC Cardiovascular Disorders 23:1.
Crossref
Yin Zhao, Chen Zhang, Haiyuan Su, Xiaoyang Yin, Xinlei Liu, Hou Hou, Gaoya Wang, Dong Li, Na Zhang & Wei Wei. (2023) Predictive factors for progressive fibrosing interstitial lung disease in anti‐synthetase syndrome. International Journal of Rheumatic Diseases 26:5, pages 885-894.
Crossref
Laura M. Glenn, Lauren K. Troy & Tamera J. Corte. (2023) Novel diagnostic techniques in interstitial lung disease. Frontiers in Medicine 10.
Crossref
Jaleel Jerry G. Sweis, Nabil W. G. Sweis, Fatima Alnaimat, Jacqueline Jansz, Ting-Wei Ernie Liao, Alaa Alsakaty, Abeera Azam, Hesham Elmergawy, Hali A. Hanson, Christian Ascoli, Israel Rubinstein & Nadera Sweiss. (2023) Immune-mediated lung diseases: A narrative review. Frontiers in Medicine 10.
Crossref
Onofre Moran-Mendoza, Ahmad Al-Jarallah, Salem Alqahtani & Carla Paredes. (2023) What could explain the high prevalence of progressive fibrosing interstitial lung disease in a patient registry?. European Respiratory Journal 61:4, pages 2300019.
Crossref
Diego Durán Barata, Ana Jaureguizar Oriol, Jesús Loarce Martos, Jose Luis Morell Hita, Carlos de la Puente Bujidos & Juan Rigual Bobillo. (2023) Progressive pulmonary fibrosis in systemic autoimmune diseases. A real life study. Reumatología Clínica (English Edition) 19:4, pages 211-214.
Crossref
Diego Durán Barata, Ana Jaureguizar Oriol, Jesús Loarce Martos, Jose Luis Morell Hita, Carlos de la Puente Bujidos & Juan Rigual Bobillo. (2023) Fibrosis pulmonar en enfermedades autoinmunes sistémicas. Un estudio en vida real. Reumatología Clínica 19:4, pages 211-214.
Crossref
Kyung-In Joung, Hyemin Park, Sunyoung Park, Ju-Young Shin & Yong Hyun Kim. (2023) Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study. BMC Pulmonary Medicine 23:1.
Crossref
Lavanya Raman, Iain Stewart, Shaney L. Barratt, Felix Chua, Nazia Chaudhuri, Anjali Crawshaw, Michael Gibbons, Charlotte Hogben, Rachel Hoyles, Vasilis Kouranos, Jennifer Martinovic, Sarah Mulholland, Katherine J. Myall, Marium Naqvi, Elisabetta A. Renzoni, Peter Saunders, Matthew Steward, Dharmic Suresh, Muhunthan Thillai, Athol U. Wells, Alex West, Jane A. Mitchell & Peter M. George. (2023) Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Research 9:2, pages 00423-2022.
Crossref
Sujeet K. Rajan, Vincent Cottin, Raja Dhar, Sonye Danoff, Kevin R. Flaherty, Kevin K. Brown, Anant Mohan, Elizabeth Renzoni, Murali Mohan, Zarir Udwadia, Padmanabha Shenoy, David Currow, Anand Devraj, Bhavin Jankharia, Ritu Kulshrestha, Steve Jones, Claudia Ravaglia, Silvia Quadrelli, Rajam Iyer, Sahajal Dhooria, Martin Kolb & Athol U. Wells. (2023) Progressive pulmonary fibrosis: an expert group consensus statement. European Respiratory Journal 61:3, pages 2103187.
Crossref
Masato Kono, Tomo Tsunoda, Shin Ikeda, Shota Yagi, Ryutaro Hirama, Masayuki Watanuki, Yuiko Oshima, Akari Tsutsumi, Hideki Miwa, Yoshihiro Miki, Dai Hashimoto, Takafumi Suda & Hidenori Nakamura. (2023) Clinical features of idiopathic pleuroparenchymal fibroelastosis with progressive phenotype showing a decline in forced vital capacity. Respiratory Investigation 61:2, pages 210-219.
Crossref
Farida Ahangari, Nathan L. Price, Shipra Malik, Maurizio Chioccioli, Thomas Bärnthaler, Taylor S. Adams, Jooyoung Kim, Sai Pallavi Pradeep, Shuizi Ding, Carlos CosmosJr.Jr., Kadi-Ann S. Rose, John E. McDonough, Nachelle R. Aurelien, Gabriel Ibarra, Norihito Omote, Jonas C. Schupp, Giuseppe DeIuliis, Julian A. Villalba Nunez, Lokesh Sharma, Changwan Ryu, Charles S. Dela Cruz, Xinran Liu, Antje Prasse, Ivan Rosas, Raman Bahal, Carlos Fernández-Hernando & Naftali Kaminski. (2023) microRNA-33 deficiency in macrophages enhances autophagy, improves mitochondrial homeostasis, and protects against lung fibrosis. JCI Insight 8:4.
Crossref
Kristin Berger & Robert J. Kaner. (2023) Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. Life 13:3, pages 599.
Crossref
Stefan Cristian Stanel & Pilar Rivera-Ortega. (2023) Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases. Frontiers in Medicine 10.
Crossref
Jürgen Behr, Francesco Bonella, Björn C. Frye, Andreas Günther, Lars Hagmeyer, Jörg Henes, Philipp Klemm, Dirk Koschel, Michael Kreuter, Gabriela Leuschner, Dennis Nowak, Antje Prasse, Bernd QuadderHelmut Sitter & Ulrich Costabel. (2023) Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen. Pneumologie 77:02, pages 94-119.
Crossref
Katharina Buschulte, Michael Kreuter, Udo Schneider & Vincent Casteleyn. (2022) „Enthusiast meets the Experienced“: Pneumo meets … RheumatologieEnthusiast meets the experienced: pneumo meets … rheumatology. Zeitschrift für Pneumologie 20:1, pages 20-32.
Crossref
Giuliana Cerro Chiang & Tanyalak Parimon. (2023) Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. International Journal of Molecular Sciences 24:3, pages 2405.
Crossref
Maria S. Nashatyreva, Irina N. Trofimenko, Boris A. Chernyak & Sergey N. Avdeev. (2023) Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. Life 13:1, pages 212.
Crossref
SVeni Krishna. (2023) Review article on hypersensitivity pneumonitis. PULMON 25:3, pages 75.
Crossref
Ayana Suzuki, Koichiro Kamio, Mitsuhiro Takeno, Yasuhiro Terasaki, Namiko Taniuchi, Junpei Sato, Nobuhiko Nishijima, Yoshinobu Saito, Masahiro Seike, Akihiko Gemma & Arata Azuma. (2023) Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review. Therapeutic Advances in Respiratory Disease 17, pages 175346662311582.
Crossref
Fabrizio Luppi & Luca Richeldi. 2023. Orphan Lung Diseases. Orphan Lung Diseases 549 560 .
E Seixas, M Ferreira, P Serra, R Aguiar, I Cunha & P G Ferreira. (2022) Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort. African Journal of Thoracic and Critical Care Medicine, pages 163-166.
Crossref
Mona Nili, David Singer & Maya Hanna. (2022) Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype. BMC Pulmonary Medicine 22:1.
Crossref
Yozo Sato, Tomohisa Baba, Hideya Kitamura, Takashi Niwa, Shigeru Komatsu, Eri Hagiwara, Tae Iwasawa, Koji Okudela, Tamiko Takemura & Takashi Ogura. (2022) Usefulness and safety of transbronchial lung cryobiopsy for reassessment of treatment in the clinical course of diffuse parenchymal lung disease. BMC Pulmonary Medicine 22:1.
Crossref
Lisa Jungblut, André Euler, Jochen von Spiczak, Thomas Sartoretti, Victor Mergen, Vanessa Englmaier, Anna Landsmann, Carmen-Marina MihaiOliver DistlerHatem Alkadhi, Thomas Frauenfelder & Katharina Martini. (2022) Potential of Photon-Counting Detector CT for Radiation Dose Reduction for the Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis. Investigative Radiology 57:12, pages 773-779.
Crossref
Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka & Akihito Yokoyama. (2022) Lung CCR6−CXCR3− type 2 helper T cells as an indicator of progressive fibrosing interstitial lung diseases. Scientific Reports 12:1.
Crossref
Takashi Ogura, Takafumi Suda, Naohiko Inase, Yasuhiko Nishioka, Arata Azuma, Masaki Okamoto, Ayako Takizawa, Tomohiro Ito, Klaus B. Rohr & Yoshikazu Inoue. (2022) Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. Respiratory Investigation 60:6, pages 787-797.
Crossref
Jhih‐Ying Chi, Yu‐Wei Hsiao, Hsin‐Yin Liang, Tang‐Hsiu Huang, Feng‐Wei Chen, Chen‐Yang Chen, Chiung‐Yuan Ko, Chao‐Chun Cheng & Ju‐Ming Wang. (2022) Blockade of the pentraxin 3/CD44 interaction attenuates lung injury‐induced fibrosis. Clinical and Translational Medicine 12:11.
Crossref
Noriyuki Enomoto, Hyogo Naoi, Yasutaka Mochizuka, Takuya Isayama, Yuko Tanaka, Atsuki Fukada, Yuya Aono, Mineo Katsumata, Hideki Yasui, Kazutaka Mori, Masato Karayama, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Yutaro Nakamura & Takafumi Suda. (2022) Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases. BMC Pulmonary Medicine 22:1.
Crossref
Byoung Soo Kwon, Eun Sun Kim, Sung Yoon Lim, Myung Jin Song, Yeon Wook Kim, Hyung-Jun Kim, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Choon-Taek Lee & Jae Ho Lee. (2022) The significance of elevated tumor markers among patients with interstitial lung diseases. Scientific Reports 12:1.
Crossref
Wojciech Piotrowski, Magdalena Martusewicz-Boros, Adam Białas, Adam Barczyk, Bogdan Batko, Katarzyna Błasińska, Piotr Boros, Katarzyna Górska, Piotr Grzanka, Ewa Jassem, Dariusz Jastrzębski, Janina Kaczyńska, Otylia Kowal-Bielecka, Eugeniusz Kucharz, Jan Kuś, Barbara Kuźnar-Kamińska, Brygida Kwiatkowska, Renata Langfort, Katarzyna Lewandowska, Barbara Mackiewicz, Sebastian Majewski, Joanna Makowska, Joanna Miłkowska-Dymanowska, Elżbieta Puścińska, Alicja Siemińska, Małgorzata Sobiecka, Renata Soroka-Dąda, Małgorzata Szołkowska, Elżbieta Wiatr, Dariusz Ziora & Paweł Śliwiński. (2022) Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. Advances in Respiratory Medicine 90:5, pages 425-450.
Crossref
Nathan Hambly, M. Malik Farooqi, Anna Dvorkin-Gheva, Kathryn Donohoe, Kristopher Garlick, Ciaran Scallan, Sy Giin Chong, Sarah MacIsaac, Deborah Assayag, Kerri A. Johannson, Charlene D. Fell, Veronica Marcoux, Helene Manganas, Julie Morisset, Alessia Comes, Jolene H. Fisher, Shane Shapera, Andrea S. Gershon, Teresa To, Alyson W. Wong, Mohsen Sadatsafavi, Pierce G. Wilcox, Andrew J. Halayko, Nasreen Khalil, Gerard Cox, Luca Richeldi, Christopher J. Ryerson & Martin Kolb. (2022) Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal 60:4, pages 2102571.
Crossref
D. Durán Barata, W. Briceño Franquiz, J. Rigual Bobillo & A. Jaureguízar Oriol. (2022) Indicaciones de trasplante pulmonar. Medicine - Programa de Formación Médica Continuada Acreditado 13:64, pages 3791-3793.
Crossref
Claudia Valenzuela & Vincent Cottin. (2022) Epidemiology and real-life experience in progressive pulmonary fibrosis. Current Opinion in Pulmonary Medicine 28:5, pages 407-413.
Crossref
Tina Schreiber, Lars Hagmeyer, David M. Kofler, Torsten Kubacki, Konrad Frank & Winfried J. Randerath. (2022) Aktuelles zur RA-ILD. Pneumologie 76:09, pages 614-621.
Crossref
Marlies Wijsenbeek, Atsushi Suzuki & Toby M Maher. (2022) Interstitial lung diseases. The Lancet 400:10354, pages 769-786.
Crossref
Lotte Westerink, Jelmer Lennart Jens Nicolai, Maarten Jacobus Postma, Job Frank Martien van Boven & Cornelis Boersma. (2022) Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). PharmacoEconomics - Open 6:5, pages 647-656.
Crossref
N. S. Lev & Yu. L. Mizernitsky. (2022) Modern principles and prospects for drug therapy of interstitial lung diseases in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 67:3, pages 18-22.
Crossref
David SingerLindsay G S BengtsonCraig S ConoscentiAmy J AndersonLee BrekkeSharash S ShettyKevin K Brown. (2022) Burden of illness in progressive fibrosing interstitial lung disease. Journal of Managed Care & Specialty Pharmacy 28:8, pages 871-880.
Crossref
Reza Ronaghi & Scott Oh. (2022) Transbronchial Lung Cryobiopsy for Diffuse Parenchymal Lung Disease. Seminars in Respiratory and Critical Care Medicine 43:04, pages 536-540.
Crossref
Scott Oh, Reza Ronaghi, Tao He, Catherine Oberg, Colleen Channick, Irawan Susanto, Mathew Carroll, S Sam Weigt, David Sayah, Tamas Dolinay, Augustine Chung, Gregory Fishbein, Joseph P. Lynch & John A. Belperio. (2022) The safety profile of a protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe for interstitial lung disease. Respiratory Medicine 200, pages 106913.
Crossref
Yuanying Wang, Ziyun Guo, Ruimin Ma, Jingwei Wang, Na Wu, Yali Fan & Qiao Ye. (2022) Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study. Frontiers in Pharmacology 13.
Crossref
Hirofumi Chiba & Hirotaka Nishikiori. (2022) IV. Progressive Fibrosing Interstitial Lung DiseaseIV．進行性線維化を伴う間質性肺疾患. Nihon Naika Gakkai Zasshi 111:6, pages 1099-1105.
Crossref
Marya Ghazipura, Manoj J. Mammen, Derrick D. HermanStephanie M. Hon, Brittany D. Bissell, Madalina Macrea, Fayez Kheir, Yet H. KhorShandra L. Knight, Ganesh Raghu, Kevin C. Wilson & Tanzib Hossain. (2022) Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society 19:6, pages 1040-1049.
Crossref
Marya Ghazipura, Manoj J. Mammen, Brittany D. Bissell, Madalina Macrea, Derrick D. HermanStephanie M. Hon, Fayez Kheir, Yet H. KhorShandra L. Knight, Ganesh Raghu, Kevin C. Wilson & Tanzib Hossain. (2022) Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society 19:6, pages 1030-1039.
Crossref
Reoto Takei, Kevin K. Brown, Yasuhiko Yamano, Kensuke Kataoka, Toshiki Yokoyama, Toshiaki Matsuda, Tomoki Kimura, Atsushi Suzuki, Taiki Furukawa, Junya Fukuoka, Takeshi Johkoh, Yoshihito Goto & Yasuhiro Kondoh. (2022) Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology 27:5, pages 333-340.
Crossref
María Molina-Molina, Ivette Buendia-Roldan, Diego Castillo, Fabian Caro, Claudia Valenzuela & Moisés Selman. (2022) [Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos de Bronconeumología 58:5, pages T418-T424.
Crossref
María Molina-Molina, Ivette Buendia-Roldan, Diego Castillo, Fabian Caro, Claudia Valenzuela & Moisés Selman. (2022) Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva. Archivos de Bronconeumología 58:5, pages 418-424.
Crossref
M. S. Nashatyreva, I. N. Trofimenko & B. A. Chernyak. (2022) Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia). PULMONOLOGIYA 32:2, pages 199-207.
Crossref
Joshua J Solomon, Jeffrey J Swigris, Michael Kreuter, Markus Polke, Kerri Aronson, Anna-Maria Hoffmann-Vold & Paul F Dellaripa. (2022) The attitudes and practices of physicians caring for patients with rheumatoid arthritis-associated interstitial lung disease: an international survey. Rheumatology 61:4, pages 1459-1467.
Crossref
Amy L. Olson, Nadine Hartmann, Padmaja Patnaik, Elizabeth M. Garry, Rhonda L. Bohn, David Singer, Michael Baldwin & Laura Wallace. (2022) Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis. Advances in Therapy 39:4, pages 1794-1809.
Crossref
Mark Hamblin, Helmut Prosch & Martina Vašáková. (2022) Diagnosis, course and management of hypersensitivity pneumonitis. European Respiratory Review 31:163, pages 210169.
Crossref
Antoine Froidure, Katerina Antoniou, Marialuisa Bocchino & Enrico Conte. (2022) Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?. Frontiers in Immunology 13.
Crossref
Fabrizio Luppi, Marco Sebastiani, Carlo Salvarani, Elisabeth Bendstrup & Andreina Manfredi. (2021) Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nature Reviews Rheumatology 18:2, pages 85-96.
Crossref
Michael Kreuter, Toby M. Maher, Tamera J. Corte, Maria Molina-Molina, Judit Axmann, Frank Gilberg, Klaus-Uwe Kirchgaessler & Vincent Cottin. (2021) Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Advances in Therapy 39:2, pages 1081-1095.
Crossref
Lee E Morrow, Daniel Hilleman & Mark A Malesker. (2022) Management of patients with fibrosing interstitial lung diseases. American Journal of Health-System Pharmacy 79:3, pages 129-139.
Crossref
Qing Yang Yu & Xiao Xiao Tang. (2022) Irreversibility of Pulmonary Fibrosis. Aging and disease 13:1, pages 73.
Crossref
Zoran Popmihajlov, Donna J Sutherland, Gerald S Horan, Atalanta Ghosh, David A Lynch, Paul W Noble, Luca Richeldi, Theodore F Reiss & Steven Greenberg. (2022) CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research 9:1, pages e001060.
Crossref
Orlando Acosta Fernández, Myriam Aburto Barrenetxea, Ana Belén Llanos González, María Jesús Rodríguez Nieto, María Molina Molina & Claudia Valenzuela. (2022) Manejo de las enfermedades pulmonares intersticiales difusas (EPID) asociadas a enfermedades autoinmunes, por el neumólogo en las diferentes unidades de EPID en España. Open Respiratory Archives 4:1, pages 100160.
Crossref
Julie Morisset & Brett Ley. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine 275 280 .
Sebastiano Emanuele Torrisi, Nicolas Kahn, Julia Wälscher, Markus Polke, Joyce S. Lee, Philip L. Molyneaux, Francesca Maria Sambataro, Claus Peter Heussel, Carlo Vancheri & Michael Kreuter. (2021) Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Frontiers in Pharmacology 12.
Crossref
Maureen Gagliardi, Damienne Vande Berg, Charles-Edouard Heylen, Sandra Koenig, Delphine Hoton, Farah Tamirou, Thierry Pieters, Benoit Ghaye & Antoine Froidure. (2021) Real-life prevalence of progressive fibrosing interstitial lung diseases. Scientific Reports 11:1.
Crossref
Byoung Soo Kwon, Jooae Choe, Eun Jin Chae, Hee Sang Hwang, Yong-Gil Kim & Jin Woo Song. (2021) Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respiratory Research 22:1.
Crossref
Mouhamad Nasser, Sophie Larrieu, Loic Boussel, Salim Si-Mohamed, Fabienne Bazin, Sébastien Marque, Jacques Massol, Françoise Thivolet-Bejui, Lara Chalabreysse, Delphine Maucort-Boulch, Eric Hachulla, Stéphane Jouneau, Katell Le Lay & Vincent Cottin. (2021) Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respiratory Research 22:1.
Crossref
Vincent Cottin, Luca Richeldi, Ivan Rosas, Maria Otaola, Jin Woo Song, Sara Tomassetti, Marlies Wijsenbeek, Manuela Schmitz, Carl Coeck, Susanne Stowasser, Rozsa Schlenker-Herceg & Martin Kolb. (2021) Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research 22:1.
Crossref
Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, Toby M Maher, Jonathan G Goldin, Scott M Palmer, Takafumi Suda, Takashi Ogura, Anne Minnich, Xiaojiang Zhan, Giridhar S Tirucherai, Brandon Elpers, Hong Xiao, Hideaki Watanabe, R Adam Smith, Edgar D Charles & Aryeh Fischer. (2021) Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD) . BMJ Open Respiratory Research 8:1, pages e001026.
Crossref
T. Villeneuve, G. Prévot, F. Lintz, G. Mourin, G. Ferry, E. Bousquet, H. Perelroizen, T. Boghanim, G. Faviez, E. Noël-Savina, S. Collot, A. Le Borgne & A. Didier. (2021) EPIDemio : épidémiologie des pneumopathies interstitielles diffuses (PID) fibrosantes en Haute-Garonne. Revue des Maladies Respiratoires 38:10, pages 972-979.
Crossref
Kathleen Oare Lindell, Sara Jo Klein, Melinda S. Veatch, Kevin F. Gibson, Daniel J. Kass, Mehdi Nouraie & Margaret Q. Rosenzweig. (2021) Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society 18:11, pages 1811-1821.
Crossref
Tinne Goos, Laurens J. De Sadeleer, Jonas Yserbyt, Ellen De Langhe, Adriana Dubbeldam, Erik K. Verbeken, Geert M. Verleden, Marie Vermant, Johny Verschakelen, Robin Vos, Birgit Weynand, Stijn E. Verleden & Wim A. Wuyts. (2021) Defining and predicting progression in non-IPF interstitial lung disease. Respiratory Medicine 189, pages 106626.
Crossref
Lorriana E. Leard, Are M. Holm, Maryam Valapour, Allan R. Glanville, Sandeep Attawar, Meghan Aversa, Silvia V. Campos, Lillian M. Christon, Marcelo Cypel, Göran Dellgren, Matthew G. Hartwig, Siddhartha G. Kapnadak, Nicholas A. Kolaitis, Robert M. Kotloff, Caroline M. Patterson, Oksana A. Shlobin, Patrick J. Smith, Amparo Solé, Melinda Solomon, David Weill, Marlies S. Wijsenbeek, Brigitte W.M. Willemse, Selim M. Arcasoy & Kathleen J. Ramos. (2021) Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. The Journal of Heart and Lung Transplantation 40:11, pages 1349-1379.
Crossref
Xianqiu Chen, Jian Guo, Dong Yu, Bing Jie & Ying Zhou. (2021) Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases. Frontiers in Pharmacology 12.
Crossref
Yoshikazu Inoue, Takafumi Suda, Hideya Kitamura, Masaki Okamoto, Arata Azuma, Naohiko Inase, Masataka Kuwana, Shigeki Makino, Yasuhiko Nishioka, Takashi Ogura, Ayako Takizawa, Hiroyuki Ugai, Susanne Stowasser, Rozsa Schlenker-Herceg & Tsutomu Takeuchi. (2021) Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine 187, pages 106574.
Crossref
Katharina Buschulte, Anna-Maria Hoffmann-Vold, Rucsandra Dobrota, Philipp Höger, Andreas Krause & Michael Kreuter. (2021) Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien)Treatment of lung fibrosis in systemic rheumatic diseases (new treatment). Zeitschrift für Rheumatologie 80:8, pages 743-754.
Crossref
Carlo Albera, Giulia Verri, Federico Sciarrone, Elena Sitia, Mauro Mangiapia & Paolo Solidoro. (2021) Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines 9:9, pages 1237.
Crossref
Moisés Selman & Annie Pardo. (2021) From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump. American Journal of Physiology-Lung Cellular and Molecular Physiology 321:3, pages L600-L607.
Crossref
Anand Devaraj, Gianluca Milanese & Nicola Sverzellati. (2021) Thoracic computed tomography in the progressive fibrotic phenotype. Current Opinion in Pulmonary Medicine 27:5, pages 350-354.
Crossref
Yet H. Khor, Lawrence Gutman, Nebal Abu Hussein, Kerri A. Johannson, Ian N. Glaspole, Sabina A. Guler, Manuela Funke-Chambour, Thomas Geiser, Nicole S.L. Goh & Christopher J. Ryerson. (2021) Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest 160:3, pages 994-1005.
Crossref
Julie Tanguy, Lenny Pommerolle, Carmen Garrido, Martin Kolb, Philippe Bonniaud, Françoise Goirand & Pierre-Simon Bellaye. (2021) Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. International Journal of Molecular Sciences 22:17, pages 9316.
Crossref
Yu. L. Mizernitskiy & N. S. Lev. (2021) Modern problems of interstitial lung diseases in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 66:3, pages 5-11.
Crossref
Thomas Simpson, Shaney L. Barratt, Paul Beirne, Nazia Chaudhuri, Anjali Crawshaw, Louise E. Crowley, Sophie Fletcher, Michael A. Gibbons, Philippa Hallchurch, Laura Horgan, Ieva Jakaityte, Thomas Lewis, Tom McLellan, Katherine J. Myall, Ryan Miller, David J.F. Smith, Stefan Stanel, Muhunthan Thillai, Fiona Thompson, Timothy Wallis, Zhe Wu, Philip L. Molyneaux & Alex G. West. (2021) The burden of progressive fibrotic interstitial lung disease across the UK. European Respiratory Journal 58:1, pages 2100221.
Crossref
Amy L. Olson, Padmaja Patnaik, Nadine Hartmann, Rhonda L. Bohn, Elizabeth M. Garry & Laura Wallace. (2021) Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis. Advances in Therapy 38:7, pages 4100-4114.
Crossref
Yuko Waseda. (2021) III. Interstitial Lung DiseaseIII．間質性肺疾患. Nihon Naika Gakkai Zasshi 110:6, pages 1076-1084.
Crossref
Giuseppe CICCHETTI, Annemilia DEL CIELLO, Lucio CALANDRIELLO, Elisa LAROSA, Paola FRANCHI, Alessandra FARCHIONE, Manuela MEREU, Roberto IEZZI, Stefano PALMUCCI & Anna Rita LARICI. (2021) Focus on progressive fibrosing interstitial lung diseases (PF-ILDs). Journal of Radiological Review 8:2.
Crossref
Erica Farrand & Andrew H. Limper. (2021) Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems. Clinics in Chest Medicine 42:2, pages 287-294.
Crossref
John N. Shumar, Abhimanyu Chandel & Christopher S. King. (2021) Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. Journal of Clinical Medicine 10:11, pages 2285.
Crossref
Flavia V. Castelino & Teng Moua. (2021) Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatology 3:5, pages 295-304.
Crossref
Tinne Goos, Laurens J. De Sadeleer, Jonas Yserbyt, Geert M. Verleden, Marie Vermant, Stijn E. Verleden & Wim A. Wuyts. (2021) Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. Journal of Clinical Medicine 10:6, pages 1330.
Crossref
L. P. Ananyeva, I. E. Tyurin, O. A. Koneva, L. A. Garzanova & A. M. Lila. (2021) Interstitial lung disease in systemic sclerosis (systemic scleroderma). Modern Rheumatology Journal 15:1S, pages 1-62.
Crossref
Michael Kreuter, Ulf Müller-Ladner, Ulrich Costabel, Danny Jonigk & Claus Peter Heußel. (2021) The Diagnosis and Treatment of Pulmonary Fibrosis. Deutsches Ärzteblatt international.
Crossref
Mouhamad Nasser, Sophie Larrieu, Salim Si-Mohamed, Kaïs Ahmad, Loic Boussel, Marie Brevet, Lara Chalabreysse, Céline Fabre, Sébastien Marque, Didier Revel, Françoise Thivolet-Bejui, Julie Traclet, Sabrina Zeghmar, Delphine Maucort-Boulch & Vincent Cottin. (2021) Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). European Respiratory Journal 57:2, pages 2002718.
Crossref
Anna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, Cathrine Brunborg, Paolo Airó, Lidia P Ananieva, László Czirják, Serena Guiducci, Eric Hachulla, Mengtao Li, Carina Mihai, Gabriela Riemekasten, Petros P Sfikakis, Otylia Kowal-Bielecka, Antonella Riccardi & Oliver Distler. (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases 80:2, pages 219-227.
Crossref
Amy Olson, Nadine Hartmann, Padmaja Patnaik, Laura Wallace, Rozsa Schlenker-Herceg, Mouhamad Nasser, Luca Richeldi, Anna-Maria Hoffmann-Vold & Vincent Cottin. (2020) Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Advances in Therapy 38:2, pages 854-867.
Crossref
L. P. Ananieva, S. N. Avdeev, I. Е. Tyurin, A. М. Lila, A. I. Zagrebneva, А. L. Maslyanskiy, S. A. Terpigorev, I. V. Stepanyan, E. L. Lashina, O. V. Vasilieva, O. S. Lukina, E S. Pershina, А. А. Klimenko, N. A. Shostak & E. L. Nasonov. (2021) Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. Rheumatology Science and Practice 58:6, pages 631-636.
Crossref
Anna-Maria Hoffmann-Vold, Toby M. Maher, Edward E. Philpot, Ali Ashrafzadeh & Oliver Distler. (2021) Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Research 7:1, pages 00235-2020.
Crossref
Masataka Kuwana, Albert Gil-Vila & Albert Selva-O’Callaghan. (2021) Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110324.
Crossref
Anoop M. Nambiar, Christopher M. Walker & Jeffrey A. Sparks. (2021) Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Therapeutic Advances in Respiratory Disease 15, pages 175346662110397.
Crossref
Naoki Nishiyama, Masahiro Masuo, Yoshihisa Nukui, Tomoya Tateishi, Mitsuhiro Kishino, Ukihide Tateishi, Kaori Morota, Kazuyuki Ohbo & Yasunari Miyazaki. (2021) Human epididymis protein 4 is a new biomarker to predict the prognosis of progressive fibrosing interstitial lung disease. Respiratory Investigation 59:1, pages 90-98.
Crossref
Anna-Maria Hoffmann-Vold, Yannick Allanore, Elisabeth Bendstrup, Cosimo Bruni, Oliver Distler, Toby M. Maher, Marlies Wijsenbeek & Michael Kreuter. (2020) The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. Respiratory Research 21:1.
Crossref
Duncan J. Sweeney, Yet H. Khor & Nicole S.L. Goh. (2020) The unmet care needs of progressive fibrosing interstitial lung disease. Respirology 25:12, pages 1231-1232.
Crossref
L. P. Ananieva. (2020) Current therapy of interstitial pneumonia associated with systemic scleroderma. Rheumatology Science and Practice 58:5, pages 520-531.
Crossref
Anna-Maria Hoffmann-Vold & Øyvind Molberg. (2020) Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. Current Opinion in Rheumatology 32:6, pages 497-504.
Crossref
Marlies Wijsenbeek & Vincent Cottin. (2020) Spectrum of Fibrotic Lung Diseases. New England Journal of Medicine 383:10, pages 958-968.
Crossref
Amornpun Wongkarnjana, Ciaran Scallan & Martin R.J. Kolb. (2020) Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current Opinion in Pulmonary Medicine 26:5, pages 436-442.
Crossref
Laurens J. De Sadeleer, Stijn E. VerledenRobin Vos, Dirk Van Raemdonck & Geert M. Verleden. (2020) Advances in lung transplantation for interstitial lung diseases. Current Opinion in Pulmonary Medicine 26:5, pages 518-525.
Crossref
Peter M George, Paolo Spagnolo, Michael Kreuter, Goksel Altinisik, Martina Bonifazi, Fernando J Martinez, Philip L Molyneaux, Elisabetta A Renzoni, Luca Richeldi, Sara Tomassetti, Claudia Valenzuela, Carlo Vancheri, Francesco Varone, Vincent Cottin & Ulrich Costabel. (2020) Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. The Lancet Respiratory Medicine 8:9, pages 925-934.
Crossref
Xiaoting LvFeng GaoShuyu ZhangSheng ZhangXiaohui ZhouFadian DingJingwen WangQingquan ChenMin ChenQicai Liu. (2020) Maladjustment of β-CGRP/α-CGRP Regulation of AQP5 Promotes Transition of Alveolar Epithelial Cell Apoptosis to Pulmonary Fibrosis. Journal of Interferon & Cytokine Research 40:8, pages 377-388.
Crossref
Charlisa D. Gibson, Matthias C. Kugler, Himanshu Deshwal, John S. Munger & Rany Condos. (2020) Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung 198:4, pages 597-608.
Crossref
Wim A. Wuyts, Spyridon Papiris, Effrosyni Manali, Maritta Kilpeläinen, Jesper Rømhild Davidsen, Jelle Miedema, Carlos Robalo-Cordeiro, Antonio Morais, Maite Artés, Guus Asijee, David Cendoya & Stéphane Soulard. (2020) The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach. Advances in Therapy 37:7, pages 3246-3264.
Crossref
Laurens J. De Sadeleer, Tinne Goos, Jonas Yserbyt & Wim A. Wuyts. (2020) Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. Journal of Clinical Medicine 9:6, pages 1722.
Crossref
Marlies Wijsenbeek. (2020) Progress in the treatment of pulmonary fibrosis. The Lancet Respiratory Medicine 8:5, pages 424-425.
Crossref
Laurens J. De Sadeleer, Frederik Hermans, Els De Dycker, Jonas Yserbyt, Johny A. Verschakelen, Eric K. Verbeken, Geert M. Verleden, Stijn E. Verleden & Wim A. Wuyts. (2020) Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. European Respiratory Journal 55:4, pages 1901983.
Crossref
Paola Faverio, Martina Piluso, Federica De Giacomi, Matteo Della Zoppa, Roberto Cassandro, Sergio Harari, Fabrizio Luppi & Alberto Pesci. (2020) Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. Respiration 99:10, pages 838-845.
Crossref
Elisabeth Bendstrup, Janne Møller, Sissel Kronborg-White, Thomas Skovhus Prior & Charlotte Hyldgaard. (2019) Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians. Journal of Clinical Medicine 8:12, pages 2038.
Crossref
Hilary J. Goldberg. (2019) Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials. New England Journal of Medicine 381:18, pages 1775-1777.
Crossref
Vincent Cottin. (2019) Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. European Respiratory Review 28:153, pages 190109.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.